+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cerebrovascular Diseases Treatment Market by Treatment Modality, Products, Disease Type, End-user - Global Forecast 2025-2030- Product Image
Cerebrovascular Diseases Treatment Market by Treatment Modality, Products, Disease Type, End-user - Global Forecast 2025-2030- Product Image
Sale

Cerebrovascular Diseases Treatment Market by Treatment Modality, Products, Disease Type, End-user - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5968153
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cerebrovascular Diseases Treatment Market grew from USD 5.12 billion in 2023 to USD 5.40 billion in 2024. It is expected to continue growing at a CAGR of 5.76%, reaching USD 7.59 billion by 2030.

The scope of the cerebrovascular diseases treatment market encompasses a wide range of diagnostic and therapeutic options aimed at preventing, managing, and curing conditions affecting blood flow to the brain, such as strokes and aneurysms. Driven by an aging population and the escalating prevalence of lifestyle-related risk factors, such as hypertension and diabetes, the necessity for advanced treatment solutions continues to rise. Applications of these treatments span pharmaceuticals, minimally invasive surgical devices, and non-invasive procedures with end-users that include hospitals, clinics, and rehabilitation centers. The market's growth is substantially influenced by technological advancements, heightened health awareness, and increased healthcare expenditures, laying the groundwork for innovative treatments like telemedicine and AI-based diagnostics. Emerging markets present substantial opportunities due to lower penetration of advanced therapies and government initiatives aimed at improving healthcare infrastructure. To capture these opportunities, businesses should invest in research and development focusing on next-generation therapies and personalized medicine approaches. However, the market faces challenges such as high cost of treatment, stringent regulatory guidelines, and a shortage of skilled healthcare professionals, especially in less developed geographies. Competition from alternative treatments and generic drugs also pressures pricing strategies and margins. Despite these limitations, research and innovation areas like biomarker development, gene therapy, and wearable monitoring devices offer promising avenues for growth. The nature of the market is dynamic, characterized by rapid technological changes and a shift towards value-based care systems. Strategic partnerships and collaborations with research institutions could foster advancements and expand market reach. Companies should focus on enhancing the accessibility and affordability of treatment options, while maintaining compliance with regulatory standards to leverage market potential fully. Addressing socio-economic barriers and investing in professional training can enhance service provision and patient outcomes, driving future growth.

Understanding Market Dynamics in the Cerebrovascular Diseases Treatment Market

The Cerebrovascular Diseases Treatment Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing awareness regarding cerebrovascular diseases and the importance of early screening
    • The rising aging population globally and the increasing healthcare expenditures
  • Market Restraints
    • High cost of cerebrovascular treatment
  • Market Opportunities
    • Substantial R&D initiatives in neurovascular care
    • Advancements in devices used for cerebrovascular disease treatment
  • Market Challenges
    • Risk of side effects and lack of skilled professional

Exploring Porter’s Five Forces for the Cerebrovascular Diseases Treatment Market

Porter’s Five Forces framework further strengthens the insights of the Cerebrovascular Diseases Treatment Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Cerebrovascular Diseases Treatment Market

External macro-environmental factors deeply influence the performance of the Cerebrovascular Diseases Treatment Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Cerebrovascular Diseases Treatment Market

The Cerebrovascular Diseases Treatment Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Cerebrovascular Diseases Treatment Market

The Cerebrovascular Diseases Treatment Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Cerebrovascular Diseases Treatment Market

The Cerebrovascular Diseases Treatment Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cerebrovascular Diseases Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca, AstraZeneca plc, Bayer AG, BIOGEN INC., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Daiichi Sankyo Co. Ltd., GE HealthCare Technologies Inc., Genentech, Inc., Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Medtronic plc, Merck & Co., Inc., Penumbra, Inc., Pfizer Inc., Sangamo Therapeutics, Inc., Sanofi SA, Siemens Healthineers AG, Sihuan Pharmaceutical Holdings Group Ltd., Takeda Pharmaceutical Co. Ltd., and United Therapeutics Corp..

Market Segmentation & Coverage

This research report categorizes the Cerebrovascular Diseases Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Treatment Modality
    • Endovascular Procedures
    • Medical Management
    • Surgical Intervention
  • Products
    • Devices
      • Carotid Stents
      • Cerebral Balloon Angioplasty and Stenting Systems
      • Clot Retrieval Devices
      • Coil Embolization Devices
      • Embolic Protection Systems
      • Flow Diverter Devices
      • Intracranial Stents
    • Drug Medication
      • Anticoagulants
      • Antihypertensive Drugs
      • Antiplatelet Drugs
      • Cholesterol-lowering Drugs
      • Thrombolytics
  • Disease Type
    • Hemorrhagic Stroke
    • Ischemic Stroke
    • Transient Ischemic Attack (TIA)
  • End-user
    • Ambulatory Care Centers
    • Hospitals & Surgical Centers
    • Research Laboratories & Academic Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing awareness regarding cerebrovascular diseases and the importance of early screening
5.1.1.2. The rising aging population globally and the increasing healthcare expenditures
5.1.2. Restraints
5.1.2.1. High cost of cerebrovascular treatment
5.1.3. Opportunities
5.1.3.1. Substantial R&D initiatives in neurovascular care
5.1.3.2. Advancements in devices used for cerebrovascular disease treatment
5.1.4. Challenges
5.1.4.1. Risk of side effects and lack of skilled professional
5.2. Market Segmentation Analysis
5.2.1. Treatment Modality: Growing adoption of endovascular procedures owing to their minimally invasive nature
5.2.2. End-user: Increasing need for cerebrovascular diseases treatment in hospitals and surgical centers
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Cerebrovascular Diseases Treatment Market, by Treatment Modality
6.1. Introduction
6.2. Endovascular Procedures
6.3. Medical Management
6.4. Surgical Intervention
7. Cerebrovascular Diseases Treatment Market, by Products
7.1. Introduction
7.2. Devices
7.2.1. Carotid Stents
7.2.2. Cerebral Balloon Angioplasty and Stenting Systems
7.2.3. Clot Retrieval Devices
7.2.4. Coil Embolization Devices
7.2.5. Embolic Protection Systems
7.2.6. Flow Diverter Devices
7.2.7. Intracranial Stents
7.3. Drug Medication
7.3.1. Anticoagulants
7.3.2. Antihypertensive Drugs
7.3.3. Antiplatelet Drugs
7.3.4. Cholesterol-lowering Drugs
7.3.5. Thrombolytics
8. Cerebrovascular Diseases Treatment Market, by Disease Type
8.1. Introduction
8.2. Hemorrhagic Stroke
8.3. Ischemic Stroke
8.4. Transient Ischemic Attack (TIA)
9. Cerebrovascular Diseases Treatment Market, by End-user
9.1. Introduction
9.2. Ambulatory Care Centers
9.3. Hospitals & Surgical Centers
9.4. Research Laboratories & Academic Institutes
10. Americas Cerebrovascular Diseases Treatment Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Cerebrovascular Diseases Treatment Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Cerebrovascular Diseases Treatment Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Cerenovus Launched Cereglide 71 Intermediate Catheter for Revascularization in Patients with Acute Ischemic Stroke
13.3.2. Enzene Biosciences Launched Biosimilar to Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration (AMD)
13.3.3. Cooper And Inspira Partner to Expand Neuroscience Care In South Jersey
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. CEREBROVASCULAR DISEASES TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. CEREBROVASCULAR DISEASES TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. CEREBROVASCULAR DISEASES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CEREBROVASCULAR DISEASES TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CEREBROVASCULAR DISEASES TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY MEDICAL MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CAROTID STENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CEREBRAL BALLOON ANGIOPLASTY AND STENTING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CLOT RETRIEVAL DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COIL EMBOLIZATION DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY FLOW DIVERTER DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY INTRACRANIAL STENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TRANSIENT ISCHEMIC ATTACK (TIA), BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY HOSPITALS & SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 56. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 57. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 58. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 60. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 62. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 64. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 65. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 66. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 88. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 89. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 90. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 91. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 92. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 94. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 95. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 96. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 97. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 98. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 103. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 104. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 106. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 107. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 108. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 109. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 110. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 115. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 116. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 121. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 122. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 127. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 128. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 133. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 134. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 139. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 140. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 142. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 143. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 144. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 145. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 146. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 151. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 152. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 160. DENMARK CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 161. DENMARK CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 162. DENMARK CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 163. DENMARK CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 164. DENMARK CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 165. DENMARK CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 166. EGYPT CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 167. EGYPT CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 168. EGYPT CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 169. EGYPT CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 170. EGYPT CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 171. EGYPT CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. FINLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 173. FINLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 174. FINLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 175. FINLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 176. FINLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 177. FINLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. FRANCE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 179. FRANCE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 180. FRANCE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 181. FRANCE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 182. FRANCE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 183. FRANCE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. GERMANY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 185. GERMANY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 186. GERMANY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 187. GERMANY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 188. GERMANY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 189. GERMANY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 194. ISRAEL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 195. ISRAEL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. ITALY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 197. ITALY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 198. ITALY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 199. ITALY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 200. ITALY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 201. ITALY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 214. NORWAY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 215. NORWAY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 216. NORWAY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 217. NORWAY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 218. NORWAY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 219. NORWAY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 220. POLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 221. POLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 222. POLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 223. POLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 224. POLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 225. POLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 226. QATAR CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 227. QATAR CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 228. QATAR CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 229. QATAR CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 230. QATAR CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 231. QATAR CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 250. SPAIN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 251. SPAIN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 252. SPAIN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 253. SPAIN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 254. SPAIN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 255. SPAIN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 261. SWEDEN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 268. TURKEY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 269. TURKEY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 270. TURKEY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 271. TURKEY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 272. TURKEY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 273. TURKEY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
TABLE 284. UNITED KINGDOM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 286. CEREBROVASCULAR DISEASES TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 287. CEREBROVASCULAR DISEASES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Cerebrovascular Diseases Treatment Market, which are profiled in this report, include:
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca
  • AstraZeneca plc
  • Bayer AG
  • BIOGEN INC.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • GE HealthCare Technologies Inc.
  • Genentech, Inc.
  • Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Medtronic plc
  • Merck & Co., Inc.
  • Penumbra, Inc.
  • Pfizer Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • United Therapeutics Corp.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.4 Billion
Forecasted Market Value ( USD ) by 2030 $ 7.59 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Stroke and Cerebrovascular Disease in Childhood. Edition No. 1. International Review of Child Neurology - Product Image

Stroke and Cerebrovascular Disease in Childhood. Edition No. 1. International Review of Child Neurology

  • Book
  • 248 Pages
  • Global
Cerebral Dural Arteriovenous Fistulas - Product Image

Cerebral Dural Arteriovenous Fistulas

  • Book
Stroke Part I: Basic and epidemiological aspects. Handbook of Clinical Neurology Volume 92 - Product Image

Stroke Part I: Basic and epidemiological aspects. Handbook of Clinical Neurology Volume 92

  • Book
Neurological Disease Treatment Market Report and Forecast 2024-2032 - Product Image

Neurological Disease Treatment Market Report and Forecast 2024-2032

  • Report
  • 240 Pages
  • Global
From
Stroke. Pathophysiology, Diagnosis, and Management. Edition No. 7 - Product Image

Stroke. Pathophysiology, Diagnosis, and Management. Edition No. 7

  • Book

About the Cerebrovascular Diseases Drug Market

The Cerebrovascular Diseases Drug market is a subset of the Cardiovascular Drugs market, focusing on drugs used to treat cerebrovascular diseases. These drugs are used to treat conditions such as stroke, transient ischemic attack, and cerebral aneurysm. They are typically administered orally or intravenously, and may include anticoagulants, antiplatelet agents, thrombolytics, and vasodilators. The Cerebrovascular Diseases Drug market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, Bristol-Myers Squibb, and Novartis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.